@eScotty,
Certain factors increase the risk of developing Tardive Dyskinesia (TD)
Quote:Typical risk factors associated with the development of TD (Tardive Dyskinesia) include older age, pre-existing movement or neurodegenerative disorders, female sex, the presence of affective illness, and neuroleptic exposure of more than six months.
Abilify is considered a second-generation atypical anti-psychotic drug. It was developed primarily for the treatment of schizophrenia. All anti-psychotic drugs increase the risk of TD, particularly at higher doses, or when taken for longer than six months. This risk is lower with the the second generation anti-psychotics, such as Abilify.
Prescribing Abilify as an adjunct in the treatment of depression is an "off-label" use of the drug, since the primary use is as an anti-psychotic. In low doses, and when taken for less than six months, the risk of TD with Abilify is relatively minimal, but some risk is present, particularly in older patients. This is why use of Abilify should be carefully monitored by a physician. Generally, if the drug is withdrawn at the first sign of TD symptoms, the symptoms generally reverse and do not remain permanent, particularly if the drug has been used less than six months.
No medication is risk free. You and your doctor have to balance the reward of possibly enhanced treatment for depression against the risks associated with the drug. You should discuss your concerns with your physician since that person is aware of any particular risk factors in your case.